A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).


The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Full Title of Study: “A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 20, 2019


  • Drug: placebo
    • Placebo solution for IV infusion
  • Drug: ABBV-8E12
    • ABBV-8E12 solution for IV infusion

Arms, Groups and Cohorts

  • Placebo Comparator: Group 3
    • Placebo for ABBV-8E12
  • Experimental: Group 1
    • Dose 1 ABBV-8E12
  • Experimental: Group 2
    • Dose 2 ABBV-8E12

Clinical Trial Outcome Measures

Primary Measures

  • Change from Baseline to Week 52 in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score
    • Time Frame: Baseline, Week 52
    • The PSPRS is a 28-item scale comprising 6 domains (daily activities, mentation, bulbar, ocular motor, limb motor, and gait/midline).
  • Adverse Events
    • Time Frame: 68 weeks

Secondary Measures

  • Time to Cmax (Tmax) for ABBV-8E12
    • Time Frame: 16 weeks
  • Change from Baseline to Week 52 in Clinical Global Impression of Change (CGI-C)
    • Time Frame: Baseline, Week 52
    • The CGI-C is a clinician’s rating of improvement in disease severity.
  • Midbrain Atrophy As Measured by Volumetric Magnetic Resonance Imaging (MRI)
    • Time Frame: Baseline, Week 52
    • Midbrain atrophy as measured by change in volumetric MRI from baseline to Week 52.
  • Area under the concentration time curve (AUC) for ABBV-8E12
    • Time Frame: 16 weeks
  • Maximum observed serum concentration (Cmax) for ABBV-8E12
    • Time Frame: 16 weeks
  • Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12
    • Time Frame: 52 weeks
  • Change from Baseline to Week 52 in Unified Parkinson’s Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)
    • Time Frame: Baseline, Week 52
    • The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson’s disease.
  • Change from Baseline to Week 52 in Schwab and England Activities of Daily Living Scale (SEADL)
    • Time Frame: Baseline, Week 52
    • The SEADL assesses the subject’s ability to perform daily activities.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subject with age 40 years or greater at the time of signed consent. – Meets the criteria for possible or probable progressive supranuclear palsy (Steele-Richardson-Olszewski Syndrome). – Presence of PSP symptoms for less than 5 years. – Subject is able to walk 5 steps with minimal assistance (stabilization of one arm or use of cane/walker). – Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend). Exclusion Criteria:
  • Subjects who weigh less than 44 kg (97 lbs) at screening. – MMSE score less than 15 at screening. – Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI). – Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period. – Evidence of any clinically significant neurological disorder other than PSP. – The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria. – Subject has had a significant illness or infection requiring medical intervention in the past 30 days.
  • Gender Eligibility: All

    Minimum Age: 40 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • AbbVie
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • AbbVie Inc., Study Director, AbbVie

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.